CEO Brian Kocher is highly confident in the business's direction, reaffirming the 2024 outlook. The company's growth is expected to be driven by nutritional beverages expansion and Better-For-You snacking segment acceleration.
SunOpta CEO marks the sale as a key point in transforming to concentrate on plant-based and healthy snack segments. The move is expected to boost margins, enable a more capital-efficient model, strengthen finances and pave way for attractive growth opportunities.
Stocks with Josh楼主AMAYA1728:
We may be early on Mara if we get a run on bitcoin up to 25,000 Mara will climb but in general I see Mara still moving down for the next four months so there could be a short term pop but a longer trend down
Gainers: •$Okta(OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo(STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
SunOpta股票讨论区
👀
+Technical Tuesday Stocks of Interest
专栏Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
暂无评论